Britain and America have forged a landmark trade agreement that will ensure zero duties on British medicine products going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to increase funding on pharmaceuticals through the NHS. This commitment ensures that duties on these crucial exports will stay at nothing for a timeframe of the next three years.
This development comes after earlier threats to hike duties on branded pharmaceutical products, with figures floated reaching double the cost.
"This deal with the UK strengthens the international landscape for innovative medicines and introduces much-needed balance to American-British medicine commerce," an announcement said.
Economic Importance
Medicines are one of the Britain's biggest export categories to the US, which is easily the largest buyer for leading British pharmaceutical firms.
Export figures reveal that in the year prior to the third quarter, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value made up a significant portion of total UK exports in that timeframe.
"This guarantee secures employment, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a government official commented.
Detailed British Pledges
The pact includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to control costs will be restricted at 15%. Last year, rebates topped 20%.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
These tensions were intensified by arguments that US patients were paying a premium for the identical medicines than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or cancelled, while major funding commitments have been pledged toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the previous ten-year period.
